top of page
![Case 1 rescan 08102023_Scan1_[9306,47114]_composite_image copy.jpg](https://static.wixstatic.com/media/01ddd9_a4b7417e4a1f45a08a6542b77197a49d~mv2.jpg/v1/fill/w_229,h_172,al_c,q_80,usm_0.66_1.00_0.01,enc_avif,quality_auto/01ddd9_a4b7417e4a1f45a08a6542b77197a49d~mv2.jpg)
Welcome to BurrLab!
In the Burr laboratory, we employ genome scale CRISPR genetic screening approaches, together with genomic and proteomic technologies, to uncover novel therapeutic targets to enhance immune recognition of cancer cells. We aim to both establish new approaches to enhance the efficacy of existing immunotherapies and develop new immune-based therapies to treat solid and haematological malignancies.
"Somewhere, something incredible is waiting to be known"
- Carl Sagan
Research & Discoveries
Inhibition of the CtBP complex and FBXO11 enhances MHC class II expression and anti-cancer immune responses
An evolutionarily conserved function of polycomb silences the MHC class I antigen presentation pathway and enables immune evasion in cancer
Latest Publications
Retention prediction of analytes in reversed-phase high-performance liquid chromatography based on molecular structure DOI: 10.1016/S0021-9673(01)89663-1
Targeting Menin disrupts the KMT2A/B and polycomb balance to paradoxically activate bivalent genes. Nature Cell Biology. 2023. https://rdcu.be/c3i5t.
bottom of page